- Home
- AXR vs CHRS Comparison
AXR vs CHRS Comparison
Compare AXR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXR
- CHRS
- Stock Information
- Founded
- AXR 1961
- CHRS 2010
- Country
- AXR United States
- CHRS United States
- Employees
- AXR N/A
- CHRS N/A
- Industry
- AXR Homebuilding
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AXR Real Estate
- CHRS Health Care
- Exchange
- AXR Nasdaq
- CHRS Nasdaq
- Market Cap
- AXR 110.0M
- CHRS 112.5M
- IPO Year
- AXR N/A
- CHRS 2014
- Fundamental
- Price
- AXR $21.79
- CHRS $0.97
- Analyst Decision
- AXR
- CHRS Strong Buy
- Analyst Count
- AXR 0
- CHRS 4
- Target Price
- AXR N/A
- CHRS $5.26
- AVG Volume (30 Days)
- AXR 13.1K
- CHRS 1.7M
- Earning Date
- AXR 03-07-2025
- CHRS 05-12-2025
- Dividend Yield
- AXR N/A
- CHRS N/A
- EPS Growth
- AXR 472.07
- CHRS N/A
- EPS
- AXR 2.41
- CHRS 0.25
- Revenue
- AXR $58,052,000.00
- CHRS $266,959,999.00
- Revenue This Year
- AXR N/A
- CHRS N/A
- Revenue Next Year
- AXR N/A
- CHRS $9.02
- P/E Ratio
- AXR $9.09
- CHRS $3.90
- Revenue Growth
- AXR 30.35
- CHRS 3.78
- 52 Week Low
- AXR $15.88
- CHRS $0.66
- 52 Week High
- AXR $39.67
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- AXR 47.78
- CHRS 48.50
- Support Level
- AXR $21.15
- CHRS $0.92
- Resistance Level
- AXR $22.97
- CHRS $1.12
- Average True Range (ATR)
- AXR 1.06
- CHRS 0.07
- MACD
- AXR -0.09
- CHRS -0.01
- Stochastic Oscillator
- AXR 23.78
- CHRS 21.28
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve the obtaining of approvals and the sale of both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.